Study of a new targeted drug for HER2-positive advanced cancers
Part of Cancer clinical trials.
This study tests an investigational drug (KM501) for advanced solid tumors that have HER2 changes. It aims to see if the drug can shrink tumors or slow their growth, and whether it is safe for patients who have run out of standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 74 years old.
- You must have advanced cancer that has not responded to standard treatments or no standard treatment exists.
- You must be HER2-positive, HER2-expressing, or have HER2 amplification/mutation, confirmed by a test.
- You must be able to perform daily activities with minimal help (ECOG score 0 or 1).
- Your cancer must be measurable or evaluable by scans.
- You must have adequate organ function (kidney, liver, blood counts) and be willing to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (SHR-4602) alone or with other treatments for advanced solid tumors that have HER2. The goal is to see if it can shrink or control the cancer.
This trial tests a new drug called KH801, which may help the immune system fight cancer. It's for people whose cancer has spread or can't be removed and who have already tried other treatments without success. The goal is to see if the drug is safe and if it helps slow down the cancer.
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This study tests a new drug called KM257 for people with advanced solid tumors that have a high level of a protein called HER2. The drug is given as an infusion and is designed to target cancer cells with this protein, potentially slowing or stopping tumor growth.
This trial tests an experimental drug called KM602 for people with advanced solid tumors that have stopped responding to standard treatments, particularly melanoma and non-small cell lung cancer. It aims to see if the drug is safe and effective in shrinking or controlling tumors.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.